Related Experiment Video

Updated: Mar 25, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.8K

Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management

Srinath Sundararajan1, Abhijeet Kumar1, Mugilan Poongkunran2

  • 1Division of Hematology & Oncology, Department of Medicine, University of Arizona, Tucson, AZ, USA.

Future Oncology (London, England)
|February 23, 2016
PubMed

Insights

Newer anticancer drugs targeting vascular endothelial growth factor (VEGF) offer personalized care but can cause cardiovascular adverse effects. Understanding these risks is crucial for safe and effective cancer treatment.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Anticancer therapies have advanced, incorporating targeted agents like those inhibiting receptor tyrosine kinases (VEGFR, EGFR).
  • These targeted therapies represent a shift towards personalized cancer care.
  • While effective, novel anticancer drugs present unique side-effect profiles, notably cardiovascular adverse events.

Purpose of the Study:

  • To review the cardiovascular adverse effects associated with anti-vascular endothelial growth factor (anti-VEGF) therapy.
  • To highlight the importance of understanding these side effects for optimizing patient outcomes.

Main Methods:

  • Literature review focusing on cardiovascular adverse effects of anti-VEGF agents.
  • Analysis of reported cardiovascular complications in clinical studies and case reports.

Main Results:

  • Anti-VEGF therapies are associated with a spectrum of cardiovascular adverse effects.
  • Specific cardiovascular toxicities include hypertension, cardiac ischemia, and thromboembolic events.
  • The incidence and severity of these effects vary depending on the specific anti-VEGF agent and patient factors.

Conclusions:

  • Cardiovascular adverse effects are a significant concern with anti-VEGF therapy.
  • Close monitoring and proactive management of cardiovascular risks are essential for patients receiving anti-VEGF treatment.
  • Further research is needed to elucidate the mechanisms and develop strategies for mitigating these adverse events.
Keywords:
adverse effectsangiogenesis inhibitorsanti-VEGF therapycardiovasculartyrosine kinase inhibitors

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
633
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
547
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K